Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
“I don't think anyone should be surprised if the HARMONY three study reads out positively. Of course, we need to wait another six or so, maybe nine months for for that data.”
→ Read the source episode
Our resolution criterion
disputableHARMONY three trial results are published and show positive efficacy on primary endpoint.
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Brian Skorney predicts Novartis will present full DM1 trial dataset at WMS (World Muscle Society) conference in Japan within a few weeks.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.